Werewolf Therapeutics, Inc. Common Stock (HOWL) Stock Price

HOWLStock

$0.98−41.32%52W

Market Cap$47.63M

P/E—

PEG Ratio—

Div yield—

Beta0.56

HOWL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-3.09%

Price vs S&P 500 (4W)1.33%

VGM Score68.42

Book Value / Share (Quarterly)$0.34

P/TBV (Annual)0.71x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.62

Price vs S&P 500 (YTD)42.77%

Net Profit Margin (TTM)17.48%

EPS (TTM)$-0.73

10-Day Avg Trading Volume0.48M

EPS Excl Extra (TTM)$-0.73

EPS (Annual)$-1.32

ROI (Annual)-114.67%

Cash / Share (Quarterly)$0.45

ROA (Last FY)-87.64%

EBITD / Share (TTM)$-0.65

ROE (5Y Avg)-90.31%

Operating Margin (TTM)18.11%

Cash Flow / Share (Annual)$-1.24

P/B Ratio2.92x

P/B Ratio (Quarterly)1.07x

Net Income / Employee (Annual)$-1,559,500

EV / Revenue (TTM)1.22x

Net Interest Coverage (TTM)-27.08x

ROA (TTM)-59.88%

EPS Incl Extra (Annual)$-1.32

Current Ratio (Annual)1.62x

Quick Ratio (Quarterly)2.80x

3-Month Avg Trading Volume5.08M

52-Week Price Return-41.32%

Revenue / Employee (TTM)$538,500

Tangible BV / Share (Quarterly)$3.15

P/S Ratio (Annual)25.27x

Asset Turnover (Annual)0.01x

52-Week High$1.83

EPS Excl Extra (Annual)$-1.32

CapEx CAGR (5Y)-1.21%

26-Week Price Return6.81%

Quick Ratio (Annual)1.58x

13-Week Price Return166.30%

Total Debt / Equity (Annual)1.14x

Current Ratio (Quarterly)2.91x

Enterprise Value$25.64M

Asset Turnover (TTM)0.87x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-3740.85%

Cash / Share (Annual)$1.17

3-Month Return Std Dev219.46%

Net Income / Employee (TTM)$-887,500

ROE (Last FY)-245.20%

Net Interest Coverage (Annual)-12.41x

EPS Basic Excl Extra (Annual)$-1.32

Receivables Turnover (TTM)5.04x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.73

ROI (TTM)-82.59%

P/S Ratio (TTM)2.27x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.89

Price vs S&P 500 (52W)-56.85%

Year-to-Date Return54.70%

5-Day Price Return-0.18%

EPS Normalized (Annual)$-1.32

ROA (5Y Avg)-45.21%

Net Profit Margin (Annual)-3740.85%

Month-to-Date Return6.26%

Cash Flow / Share (TTM)$-1.04

EBITD / Share (Annual)$-1.28

Operating Margin (Annual)-3933.53%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-57.41%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.73

P/TBV (Quarterly)0.78x

P/B Ratio (Annual)1.24x

Pretax Margin (TTM)17.48%

Book Value / Share (Annual)$0.51

Price vs S&P 500 (13W)163.62%

Beta0.56x

Revenue / Share (TTM)$0.43

ROE (TTM)-166.98%

52-Week Low$0.27

vGradeB

mGradeB

vgmGradeB

HOWL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 31, 2026	-$0.32	$0.14	+145.16%(+$0.46)
Q1 2026	May 7, 2026	-$0.29	-$0.28	+5.08%(+$0.01)
Q4 2025	Mar 27, 2026	-$0.35	-$0.17	+50.96%(+$0.18)
Q3 2025	Nov 4, 2025	-$0.38	-$0.36	+5.88%(+$0.02)
Q2 2025	Aug 14, 2025	-$0.37	-$0.40	-7.14%(-$0.03)

HOWL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.20

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
HOWLWerewolf Therapeutics, Inc. Common Stock	B	—	B	2.3x	—	—	—	$0.98
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Werewolf Therapeutics, Inc. Common Stock

Werewolf Therapeutics develops cancer immunotherapies using its proprietary PREDATOR platform to engineer conditionally activated molecules. The company's INDUKINE molecules remain inactive in healthy tissue but selectively activate immune responses within the tumor microenvironment, potentially addressing the side-effect limitations of conventional immunotherapies. This targeted approach aims to combine improved therapeutic efficacy with reduced systemic toxicity.